David Hipkiss, AlveoGene executive chair

Gene ther­a­py biotech Alveo­Gene launch­es with lentivi­ral plat­form for res­pi­ra­to­ry dis­eases

New com­pa­ny Alveo­Gene, backed by ex­perts at the UK Res­pi­ra­to­ry Gene Ther­a­py Con­sor­tium (GTC), has made its de­but with a lead pro­gram for rare res­pi­ra­to­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.